Contact
As a member of our Public - Regulatory - Environment practice, Charles Maurel provides advisory and litigation support to French and international clients in various areas related to public law and environmental law, such as construction and infrastructure, energy, healthcare and defense.
Charles was admitted to the Paris Bar and then joined August Debouzy in 2020, after completing several internships with a law firm specializing in public business law and with the French Constitutional Council.
He graduated from the French business school HEC Paris and also holds a Master’s degree in Public and Regulatory Disputes from the University of Paris I Panthéon-Sorbonne. He has great expertise in the many subjects related to public law.
Paris, 2020
French | English
AD Deal
August Debouzy advised the Swiss group Holcim on the acquisition of the PRB group
August Debouzy, and in particular its German Desk, advised the Swiss group Holcim, a major player in innovative and sustainable construction solutions, on the acquisition of 100% of the PRB group, the leading independent French company in its sector offering a wide range of high-performance products for the renovation and thermal insulation of buildings.
AD Deal
August Debouzy assists Holcim in the proposed acquisition of the PRB Group
August Debouzy and in particular its German Desk is advising the Swiss group Holcim, one of the major players in innovative and sustainable construction solutions that came into existence from the merger between the French company Lafarge and the Swiss company Holcim, in connection with the negotiations on the proposed acquisition of 100% of the PRB group, the leading independent French company in its sector offering a wide range of high-performance products for the renovation and thermal insulation of buildings.
AD Article
Temporary and permanent tightening measures concerning foreign direct investments in France to protect strategic sectors
The threshold triggering the application of a – simplified – control is temporarily lowered from 25% to 10% of the voting rights of the entity subject to the investment, while biotechnology research activities have been permanently included in the list of strategic activities.
More
Publications